Optimal treatment strategies for cT2 staged adenocarcinoma of the esophagus and the gastroesophageal junction: a multinational, high-volume center retrospective cohort analysis
Objective: To evaluate outcomes after primary surgery (PS) or neoadjuvant treatment followed by surgery (NAT/S) in cT2 staged adenocarcinomas of the esophagus (EAC) and gastroesophageal junction (GEJ), a multinational high-volume center study was undertaken Background: The optimal treatment approach...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
November 2024
|
| In: |
Annals of surgery
Year: 2024, Jahrgang: 280, Heft: 5, Pages: 799-807 |
| ISSN: | 1528-1140 |
| DOI: | 10.1097/SLA.0000000000006478 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/SLA.0000000000006478 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/annalsofsurgery/fulltext/2024/11000/optimal_treatment_strategies_for_ct2_staged.14.aspx 
|
| Verfasserangaben: | Naita M. Wirsik, MD, Cezanne D. Kooij, MD, Niall Dempster, MD, PhD, Nerma Crnovrsanin, MD, Noel E. Donlon, MD, PhD, Eren Uzun, MD, Kunal Bhanot, MD, Henrik Nienhüser, MD, Daniela Polette, MD, Kammy Kewani, MD, Peter Grimminger, MD, Daniel Reim, MD, Florian Seyfried, MD, Hans F. Fuchs, MD, Suzanne S. Gisbertz, MD, PhD, Christoph-Thomas Germer, MD, Jelle P. Ruurda, MD, PhD, Fredrik Klevebro, MD, PhD, Wolfgang Schröder, MD, Magnus Nilsson, MD, PhD, John V. Reynolds, MD, Mark I. Van Berge Henegouwen, MD, PhD, Sheraz Markar, MD, PhD, Richard Van Hillegersberg, MD, PhD, Thomas Schmidt, MD, PhD, and Christiane J. Bruns, MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1928975089 | ||
| 003 | DE-627 | ||
| 005 | 20250913141701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250624s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/SLA.0000000000006478 |2 doi | |
| 035 | |a (DE-627)1928975089 | ||
| 035 | |a (DE-599)KXP1928975089 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wirsik, Naita Maren |e VerfasserIn |0 (DE-588)1213759447 |0 (DE-627)1724667513 |4 aut | |
| 245 | 1 | 0 | |a Optimal treatment strategies for cT2 staged adenocarcinoma of the esophagus and the gastroesophageal junction |b a multinational, high-volume center retrospective cohort analysis |c Naita M. Wirsik, MD, Cezanne D. Kooij, MD, Niall Dempster, MD, PhD, Nerma Crnovrsanin, MD, Noel E. Donlon, MD, PhD, Eren Uzun, MD, Kunal Bhanot, MD, Henrik Nienhüser, MD, Daniela Polette, MD, Kammy Kewani, MD, Peter Grimminger, MD, Daniel Reim, MD, Florian Seyfried, MD, Hans F. Fuchs, MD, Suzanne S. Gisbertz, MD, PhD, Christoph-Thomas Germer, MD, Jelle P. Ruurda, MD, PhD, Fredrik Klevebro, MD, PhD, Wolfgang Schröder, MD, Magnus Nilsson, MD, PhD, John V. Reynolds, MD, Mark I. Van Berge Henegouwen, MD, PhD, Sheraz Markar, MD, PhD, Richard Van Hillegersberg, MD, PhD, Thomas Schmidt, MD, PhD, and Christiane J. Bruns, MD |
| 264 | 1 | |c November 2024 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.06.2025 | ||
| 520 | |a Objective: To evaluate outcomes after primary surgery (PS) or neoadjuvant treatment followed by surgery (NAT/S) in cT2 staged adenocarcinomas of the esophagus (EAC) and gastroesophageal junction (GEJ), a multinational high-volume center study was undertaken Background: The optimal treatment approach with either NAT/S or PS for clinically staged cT2cNany or cT2N0 EAC and GEJ remains unknown due to the lack of randomized controlled trials. Methods: A retrospective analysis of prospectively maintained databases from 10 centers was performed. Between January 2012 and August 2023, 645 patients who fulfilled inclusion criteria of GEJ Siewert type I, II, or EAC with cT2 status at diagnosis underwent PS or NAT/S with curative intent. The primary endpoint was overall survival (OS). Results: In the cT2cNany cohort, 192 patients (29.8%) underwent PS and 453 (70.2%) underwent NAT/S. In all cT2cN0 patients (n = 333), NAT/s remained the more frequent treatment (56.2%). Patients undergoing PS were in both cT2 cohorts older (P < 0.001) and had a higher American Society of Anesthesiologists classification (P < 0.05). R0 resection showed no differences between NAT/S and PS in both cT2 cohorts (P > 0.4). Median OS was 51.0 months in the PS group (95% CI: 31.6-70.4) versus 114.0 months (95% CI: 53.9-174.1) in the NAT/S group (P = 0.003) of cT2cNany patients. For cT2cN0 patients, NAT/S was associated with longer OS (P = 0.002) and disease-free survival (P = 0.001). After propensity score matching of the cT2N0 patients, survival benefit for NAT/S remained (P = 0.004). Histopathology showed that 38.1% of cT2cNany and 34.2% of cT2cN0 patients were understaged. Conclusions: Due to the unreliable identification of cT2N0 disease, all patients should be offered a multimodal therapeutic approach. | ||
| 700 | 1 | |a Kooij, Cezanne D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dempster, Niall |e VerfasserIn |4 aut | |
| 700 | 1 | |a Crnovrsanin, Nerma |e VerfasserIn |0 (DE-588)1224835220 |0 (DE-627)174431442X |4 aut | |
| 700 | 1 | |a Donlon, Noel E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uzun, Eren |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bhanot, Kunal |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nienhüser, Henrik |d 1986- |e VerfasserIn |0 (DE-588)104690342X |0 (DE-627)777295865 |0 (DE-576)398176477 |4 aut | |
| 700 | 1 | |a Polette, Daniela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kewani, Kammy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grimminger, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reim, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seyfried, Florian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fuchs, Hans F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gisbertz, Suzanne S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Germer, Christoph-Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ruurda, Jelle P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klevebro, Fredrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schröder, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nilsson, Magnus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reynolds, John V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Van Berge Henegouwen, Mark I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Markar, Sheraz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Van Hillegersberg, Richard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmidt, Thomas |d 1980- |e VerfasserIn |0 (DE-588)132383152 |0 (DE-627)521950023 |0 (DE-576)260799149 |4 aut | |
| 700 | 1 | |a Bruns, Christiane |d 1965- |e VerfasserIn |0 (DE-588)113546602 |0 (DE-627)626118050 |0 (DE-576)322819342 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of surgery |d [Erscheinungsort nicht ermittelbar] : Lippincott Williams & Wilkins, 1885 |g 280(2024), 5 vom: Nov., Seite 799-807 |h Online-Ressource |w (DE-627)313115222 |w (DE-600)2002200-1 |w (DE-576)090881796 |x 1528-1140 |7 nnas |a Optimal treatment strategies for cT2 staged adenocarcinoma of the esophagus and the gastroesophageal junction a multinational, high-volume center retrospective cohort analysis |
| 773 | 1 | 8 | |g volume:280 |g year:2024 |g number:5 |g month:11 |g pages:799-807 |g extent:9 |a Optimal treatment strategies for cT2 staged adenocarcinoma of the esophagus and the gastroesophageal junction a multinational, high-volume center retrospective cohort analysis |
| 856 | 4 | 0 | |u https://doi.org/10.1097/SLA.0000000000006478 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/annalsofsurgery/fulltext/2024/11000/optimal_treatment_strategies_for_ct2_staged.14.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250624 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 132383152 |a Schmidt, Thomas |m 132383152:Schmidt, Thomas |d 50000 |e 50000PS132383152 |k 0/50000/ |p 25 | ||
| 998 | |g 104690342X |a Nienhüser, Henrik |m 104690342X:Nienhüser, Henrik |d 910000 |d 910200 |e 910000PN104690342X |e 910200PN104690342X |k 0/910000/ |k 1/910000/910200/ |p 8 | ||
| 998 | |g 1224835220 |a Crnovrsanin, Nerma |m 1224835220:Crnovrsanin, Nerma |d 910000 |d 910200 |e 910000PC1224835220 |e 910200PC1224835220 |k 0/910000/ |k 1/910000/910200/ |p 4 | ||
| 999 | |a KXP-PPN1928975089 |e 4738237640 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"November 2024"}],"language":["eng"],"id":{"eki":["1928975089"],"doi":["10.1097/SLA.0000000000006478"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"9 S."}],"person":[{"role":"aut","given":"Naita Maren","family":"Wirsik","display":"Wirsik, Naita Maren"},{"given":"Cezanne D.","family":"Kooij","display":"Kooij, Cezanne D.","role":"aut"},{"role":"aut","display":"Dempster, Niall","family":"Dempster","given":"Niall"},{"display":"Crnovrsanin, Nerma","family":"Crnovrsanin","given":"Nerma","role":"aut"},{"role":"aut","family":"Donlon","display":"Donlon, Noel E.","given":"Noel E."},{"given":"Eren","family":"Uzun","display":"Uzun, Eren","role":"aut"},{"role":"aut","display":"Bhanot, Kunal","family":"Bhanot","given":"Kunal"},{"given":"Henrik","family":"Nienhüser","display":"Nienhüser, Henrik","role":"aut"},{"given":"Daniela","display":"Polette, Daniela","family":"Polette","role":"aut"},{"given":"Kammy","display":"Kewani, Kammy","family":"Kewani","role":"aut"},{"family":"Grimminger","display":"Grimminger, Peter","given":"Peter","role":"aut"},{"display":"Reim, Daniel","family":"Reim","given":"Daniel","role":"aut"},{"display":"Seyfried, Florian","family":"Seyfried","given":"Florian","role":"aut"},{"display":"Fuchs, Hans F.","family":"Fuchs","given":"Hans F.","role":"aut"},{"role":"aut","family":"Gisbertz","display":"Gisbertz, Suzanne S.","given":"Suzanne S."},{"role":"aut","given":"Christoph-Thomas","display":"Germer, Christoph-Thomas","family":"Germer"},{"family":"Ruurda","display":"Ruurda, Jelle P.","given":"Jelle P.","role":"aut"},{"role":"aut","family":"Klevebro","display":"Klevebro, Fredrik","given":"Fredrik"},{"role":"aut","given":"Wolfgang","family":"Schröder","display":"Schröder, Wolfgang"},{"display":"Nilsson, Magnus","family":"Nilsson","given":"Magnus","role":"aut"},{"role":"aut","given":"John V.","family":"Reynolds","display":"Reynolds, John V."},{"role":"aut","display":"Van Berge Henegouwen, Mark I.","family":"Van Berge Henegouwen","given":"Mark I."},{"role":"aut","display":"Markar, Sheraz","family":"Markar","given":"Sheraz"},{"display":"Van Hillegersberg, Richard","family":"Van Hillegersberg","given":"Richard","role":"aut"},{"role":"aut","family":"Schmidt","display":"Schmidt, Thomas","given":"Thomas"},{"given":"Christiane","family":"Bruns","display":"Bruns, Christiane","role":"aut"}],"title":[{"title":"Optimal treatment strategies for cT2 staged adenocarcinoma of the esophagus and the gastroesophageal junction","subtitle":"a multinational, high-volume center retrospective cohort analysis","title_sort":"Optimal treatment strategies for cT2 staged adenocarcinoma of the esophagus and the gastroesophageal junction"}],"relHost":[{"language":["eng"],"id":{"eki":["313115222"],"issn":["1528-1140"],"zdb":["2002200-1"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisherPlace":"[Erscheinungsort nicht ermittelbar] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1885-","publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedKey":"1885"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Annals of surgery","subtitle":"a monthly review of surgical science and practice","title":"Annals of surgery"}],"part":{"volume":"280","text":"280(2024), 5 vom: Nov., Seite 799-807","pages":"799-807","extent":"9","year":"2024","issue":"5"},"disp":"Optimal treatment strategies for cT2 staged adenocarcinoma of the esophagus and the gastroesophageal junction a multinational, high-volume center retrospective cohort analysisAnnals of surgery","note":["Gesehen am 26.09.18"],"pubHistory":["1.1885 -"],"recId":"313115222"}],"name":{"displayForm":["Naita M. Wirsik, MD, Cezanne D. Kooij, MD, Niall Dempster, MD, PhD, Nerma Crnovrsanin, MD, Noel E. Donlon, MD, PhD, Eren Uzun, MD, Kunal Bhanot, MD, Henrik Nienhüser, MD, Daniela Polette, MD, Kammy Kewani, MD, Peter Grimminger, MD, Daniel Reim, MD, Florian Seyfried, MD, Hans F. Fuchs, MD, Suzanne S. Gisbertz, MD, PhD, Christoph-Thomas Germer, MD, Jelle P. Ruurda, MD, PhD, Fredrik Klevebro, MD, PhD, Wolfgang Schröder, MD, Magnus Nilsson, MD, PhD, John V. Reynolds, MD, Mark I. Van Berge Henegouwen, MD, PhD, Sheraz Markar, MD, PhD, Richard Van Hillegersberg, MD, PhD, Thomas Schmidt, MD, PhD, and Christiane J. Bruns, MD"]},"note":["Gesehen am 24.06.2025"],"recId":"1928975089"} | ||
| SRT | |a WIRSIKNAITOPTIMALTRE2024 | ||